版本:
中国

BRIEF-SciClone to be acquired by consortium led by GL Capital

June 8 Sciclone Pharmaceuticals Inc

* SciClone enters into definitive merger agreement to be acquired by consortium led by GL Capital

* SciClone Pharmaceuticals Inc - deal for 11.18 per share

* SciClone Pharmaceuticals Inc - deal for ‍approximately $605 million​

* Transaction, which was unanimously approved by SciClone's board, values company at approximately $605 million

* SciClone Pharmaceuticals Inc - transaction will be funded by buyer consortium through a combination of equity financing

* Says Lazard is serving as exclusive financial advisor to SciClone and DLA Piper LLP (US) is serving as its legal advisor

* Transaction was unanimously approved by SciClone's board

* SciClone Pharmaceuticals Inc - transaction will also be funded by consortium through debt financing, and is not subject to a financing condition Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐